Myriad COO has 1,069 MYGN shares withheld for taxes

Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-withholding disposition of company stock.

Rhea-AI Filing Summary

Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-withholding disposition of company stock. On April 14, 2026, 1,069 shares of Myriad Genetics common stock were withheld by the company at $4.91 per share to cover his tax obligations from previously granted restricted stock units vesting. After this withholding, Verratti directly holds 629,646 shares of Myriad Genetics common stock, indicating that the transaction represents a very small portion of his overall equity position and does not reflect an open-market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 1,069 shares

Exercise Price or Tax Liability 1 txn

Insider Verratti Mark

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,069	$4.91	$5K

Holdings After Transaction: Common Stock — 629,646 shares (Direct)

Footnotes (1)

1. F1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026.

Key Figures

Shares withheld for taxes: 1,069 shares Withholding price per share: $4.91 per share Shares held after transaction: 629,646 shares +1 more

4 metrics

Shares withheld for taxes 1,069 shares Common stock withheld to satisfy tax obligations on April 14, 2026

Withholding price per share $4.91 per share Based on MYGN closing price on April 14, 2026

Shares held after transaction 629,646 shares Direct MYGN common stock holdings following tax-withholding disposition

Tax-withholding transactions 1 transaction, 1,069 shares Aggregate tax-withholding activity in this Form 4

Key Terms

restricted stock units, tax withholding obligations, Common Stock, Form 4

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units previously granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy tax withholding obligations in connection"

Common Stock financial

"Represents shares of Common Stock withheld by the Issuer to satisfy"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MYGN COO Mark Verratti report on this Form 4?

Mark Verratti reported a tax-withholding disposition of 1,069 Myriad Genetics shares. These shares were withheld by the company to satisfy tax obligations related to vesting restricted stock units, rather than sold by Verratti in the open market.

At what price were the MYGN shares withheld for Mark Verratti’s tax obligations?

The 1,069 Myriad Genetics shares were withheld at $4.91 per share. This price was based on the closing price of Myriad Genetics common stock on April 14, 2026, as disclosed in the Form 4 footnote.

How many MYGN shares does Mark Verratti hold after this tax-withholding transaction?

After the tax-withholding transaction, Mark Verratti directly holds 629,646 shares of Myriad Genetics common stock. This shows the withheld 1,069 shares represent only a small portion of his total equity position in the company.

Was the MYGN Form 4 transaction an open-market sale by Mark Verratti?

No, the transaction was not an open-market sale. The shares were withheld by Myriad Genetics to cover Verratti’s tax obligations upon vesting of restricted stock units, a common administrative mechanism rather than a discretionary sale of shares.

What triggered the tax-withholding disposition reported by MYGN’s COO?

The disposition was triggered by the vesting of restricted stock units previously granted to Mark Verratti. When these units vested, Myriad Genetics withheld 1,069 shares to satisfy related tax withholding obligations, as described in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verratti Mark

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/14/2026		F		1,069(1)	D	$4.91	629,646	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026.

Remarks:

	By: Justin Hunter For: Mark Verratti	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)